
Oncology NEWS International
- Oncology NEWS International Vol 15 No 1
- Volume 15
- Issue 1
Trial of Tykerb for HER2-Positive Breast Cancer Brain Mets Begins
SAN ANTONIO—GlaxoSmithKline has announced the initiation of a global multicenter phase II trial (known as EGF 105084) to evaluate Tykerb (lapatinib) for the treatment of ErbB2 (HER2)-overexpressing breast cancer that has metastasized to the brain. Tykerb is an orally bioavailable small molecule that potently inhibits two receptors, ErbB2 and ErbB1. It is currently in development as a first-line treatment for ErbB2-overexpressing breast cancer.
SAN ANTONIOGlaxoSmithKline has announced the initiation of a global multicenter phase II trial (known as EGF 105084) to evaluate Tykerb (lapatinib) for the treatment of ErbB2 (HER2)-overexpressing breast cancer that has metastasized to the brain. Tykerb is an orally bioavailable small molecule that potently inhibits two receptors, ErbB2 and ErbB1. It is currently in development as a first-line treatment for ErbB2-overexpressing breast cancer.
Articles in this issue
almost 20 years ago
FDA Approves Nexavar for Use in Advanced Kidney Canceralmost 20 years ago
Avastin Benefits Metastatic Breast Canceralmost 20 years ago
Amgen to Acquire Abgenixalmost 20 years ago
Better Prognosis for ‘Elsewhere' Local Breast Ca Recurrencesalmost 20 years ago
Herceptin/Taxotere Ups DFS in Early HER2+ Breast Caalmost 20 years ago
NIH 2006 Budget Is Likely to Be Lower Than in 2005almost 20 years ago
Amooranin, a Plant Compound, Shows Potential as Cancer Treatmentalmost 20 years ago
FDA Launches 7 Initiatives With European Drug RegulatorsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.






















































































